Claritas Pharmaceuticals (TSXV:CLAS.H) - Stock Price, News & Analysis

CLAS.H Stock Overview

A clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.

About the company

CLAS.H fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

High level of non-cash earnings

Latest financial reports are more than a year old

Does not have a meaningful market cap (CA$945K)

Shares are highly illiquid

Claritas Pharmaceuticals, Inc. Competitors

Lophos Holdings

CNSX:MESC

CA$858.6k

RAMM Pharma

CNSX:RAMM

CA$1.2m

SugarBud Craft Growers

TSXV:SUGR.H

CA$718.6k

Hempsana Holdings

CNSX:HMPS

CA$591.3k

Price History & Performance

Summary of all time highs, changes and price drops for Claritas Pharmaceuticals
Historical stock prices
Current Share Price	CA$0.025
52 Week High	CA$0.025
52 Week Low	CA$0.025
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-94.68%
5 Year Change	-96.88%
Change since IPO	-99.86%

Recent updates

Shareholder Returns

	CLAS.H	CA Pharmaceuticals	CA Market
7D	0%	6.5%	-1.3%
1Y	n/a	38.5%	28.1%

Return vs Industry: Insufficient data to determine how CLAS.H performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CLAS.H performed against the Canadian Market.

Price Volatility

Is CLAS.H's price volatile compared to industry and market?
CLAS.H volatility
CLAS.H Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	3.0%

Stable Share Price: CLAS.H has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CLAS.H's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Bob Farrell	claritaspharma.com

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Claritas Pharmaceuticals, Inc. Fundamentals Summary

How do Claritas Pharmaceuticals's earnings and revenue compare to its market cap?
CLAS.H fundamental statistics
Market cap	CA$944.66k
Earnings (TTM)	CA$2.50m
Revenue (TTM)	n/a

0.0x

P/E Ratio

0.0x

P/S Ratio

Is CLAS.H overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLAS.H income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	-US$1.80m
Earnings	US$1.81m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CLAS.H perform over the long term?

See historical performance and comparison

CLAS.H Stock Overview

Rewards

Risk Analysis

Claritas Pharmaceuticals, Inc. Competitors

CNSX:MESC

CA$858.6k

CNSX:RAMM

CA$1.2m

TSXV:SUGR.H

CA$718.6k

CNSX:HMPS

CA$591.3k

Price History & Performance

Recent News & Updates

Insufficient new directors

Claritas Pharmaceuticals, Inc. Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Pharmaceuticals, Inc. Announces Receipt of Comments from Australian Ethics Committee Regarding its Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas Pharmaceuticals, Inc. to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Announces Publication of Peer-Reviewed Article Reporting That R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Recent updates

Insufficient new directors

Claritas Pharmaceuticals, Inc. Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Pharmaceuticals, Inc. Announces Receipt of Comments from Australian Ethics Committee Regarding its Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas Pharmaceuticals, Inc. to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Announces Publication of Peer-Reviewed Article Reporting That R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas Pharmaceuticals, Inc. announced that it expects to receive funding from Obsidian Global Partners, LLC

Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.18375 million in funding

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.25 million in funding

Claritas Pharmaceuticals, Inc. Announces Board Changes

Independent Interim Chairman Ronald Erickson has left the company

Independent Director has left the company

Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies

Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors

Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed

Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Claritas Pharmaceuticals to Focus on Development of R-107 as A Therapy for Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Shareholder Returns

Price Volatility

About the Company

Claritas Pharmaceuticals, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue